Skip to content

A study on Drakshadyavaleha and Devadaru syrup in the management of Bronchial Asthma in childen.

An Open Label Randomized Controlled Clinical Trial to Evaluate the Efficacy of Drakshadyavaleha and Devadaru Syrup in the Management of Tamaka Shwasa w.s.r. Bronchial Asthma in Children. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/100507
Enrollment
40
Registered
2026-01-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J45- Asthma

Interventions

None listed

Sponsors

RGGPG Ayurvedic College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children between the age group of 8 to 16 years. Patients of mild to moderate severity of Bronchial Asthma. Only stable cases of Bronchial Asthma (as per WHO GINA guideline) for at least 6 weeks prior to study. Parents/guardians of the children willing to participate in the research trial.

Exclusion criteria

Exclusion criteria: Children aged below 8 and above 16 years. Patients having Status asthmaticus condition, presenting systemic illness like Pneumonia, Pleural Effusion, Pulmonary T.B.,etc.,and patient who is suffering from any congenital or hereditary illness. Patients with PEFR less than 60%. Patients on prolonged (more than 6 weeks) medication with corticosteroids, bronchodilators, etc. Parents or guardians of the children not willing to participate in the research trial. Any other condition which the principal investigator thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of Drakshadyavaleha and Devadaru Syrup in the management of Tamaka Shwasa. To compare the efficacy of Drakshadyavaleha and Devadaru Syrup with Syrup Levosalbutamol in the management of Tamaka Shwasa. Timepoint: 3 weeks

Secondary

MeasureTime frame
To establish a safe & cost-effective medicine for the treatment of Tamaka Shwasa. To evaluate the safety of both the drugs in children. Timepoint: 3 weeks

Countries

India

Contacts

Public ContactDr Sagrika Prakash

RGGPG Ayurvedic college and Hospital, Paprola.

singhverma2024@gmail.com7018708912

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026